Clinical trials with melleril (TP21) in the treatment of schizophrenia. A two year study
| Autor: | J. D. C. Currie, R. A. Sandison, Eileen Whitelaw |
|---|---|
| Rok vydání: | 1960 |
| Předmět: |
medicine.medical_specialty
Paranoid schizophrenia Pediatrics business.industry Thioridazine 05 social sciences General Medicine 050108 psychoanalysis medicine.disease Placebo 050105 experimental psychology Clinical trial Tranquilizing Agents Schizophrenia Paraphrenia medicine 0501 psychology and cognitive sciences Psychiatry business medicine.drug |
| Zdroj: | The Journal of mental science. 106 |
| ISSN: | 0368-315X |
| Popis: | Melleril or thioridazine is one of a new series of phenothiazine derivatives which is effective in schizophrenia and is believed by the authors to be the most effective high-dose phenothiazine available for the management of the psychoses. Melleril has been given to 200 psychiatric patients over a period of 2 years. During this period it has proved itself to be safe and to be singularly free from side-effects, particularly extra-pyramidal and allergic complications. Controlled double-blind trials have demonstrated it to be superior to placebo tablets and to its close rival, KS75. Melleril is most effective in the treatment of acute and subacute schizophrenia and in the management of long-standing paranoid schizophrenia and paraphrenia. Many of these patients have been able to leave hospital and are leading normal and productive lives on long-term maintenance treatment. The dose required varies from 300 mg. to 500 mg. daily in the acute case to an average of 150 mg. daily for maintenance treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|